# Lighthouse Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/lighthouse-pharmaceuticals

- Industry: Biotechnology
- Headquarters: Novato, US
- Website: www.lighthousepharma.com/
- Total disclosed funding: $12M
- Latest round: Series A (Apr 28, 2026)
- Investors on record: 2

## About

Lighthouse Pharmaceuticals is a US-based biotechnology company focused on developing innovative therapeutics to address significant unmet medical needs in neurodegenerative diseases, particularly Alzheimer's disease.Lighthouse Pharmaceuticals specializes in therapeutics targeting neurodegenerative conditions. The company is headquartered in Novato, US. It successfully raised USD 12.00 mn in Series A funding on April 28, 2026, led by Double Point Ventures, with participation from Marin Sonoma Impact Ventures. The company has engaged in one deal to date and this funding is aimed at advancing their lead program, LHP588. The founder's history and prior ventures are not disclosed.Lighthouse Pharmaceuticals focuses on developing innovative therapeutics targeting significant unmet medical needs, primarily in the realm of neurodegenerative diseases such as Alzheimer’s disease. Its flagship product, LHP588, is a next-generation gingipain inhibitor designed for patients with P. gingivalis-positive mild to moderate Alzheimer’s disease, addressing neuroinflammation and cognitive decline linked to periodontal pathogens. The ongoing Phase 2 SPRING trial aims to enroll 300 patients in a double-blind, placebo-controlled study, targeting healthcare providers and research institutions primarily in the US and developed markets.Lighthouse Pharmaceuticals generates revenue through partnerships, financing arrangements, and clinical trial funding, emphasizing its lead program, LHP588. The revenue is bolstered by the recent USD 12.00 mn Series A financing led by Double Point Ventures, intended for advancing its therapeutic programs. Revenue streams include direct partnerships with healthcare providers and research organizations, and recent collaborations, such as with Phibro Animal Health Corporation for a periodontal health product for dogs, also contribute to revenue generation.Lighthouse Pharmaceuticals plans to utilize the recent USD 12.00 mn Series A funding to advance its lead clinical program, LHP588, and support continued pipeline expansion. The company is focused on launching new products targeting neurodegenerative diseases and aims to expand into additional geographical markets, although specific regions are not detailed. The funding will play a critical role in facilitating these initiatives, particularly in enhancing their therapeutic development.

## Funding rounds

- Series A, Apr 28, 2026, $12M — Marin Sonoma Impact Ventures, Double Point Ventures

## Investors

- Marin Sonoma Impact Ventures (https://capitalatlas.ai/funds/marin-sonoma-impact-ventures) — Series A
- Double Point Ventures (https://capitalatlas.ai/funds/double-point-ventures) — Series A